In:
Oncology, S. Karger AG, Vol. 94, No. 6 ( 2018), p. 373-382
Abstract:
〈 b 〉 〈 i 〉 Objectives: 〈 /i 〉 〈 /b 〉 We aimed to evaluate the prevalence and predictive role of 〈 i 〉 c-MET 〈 /i 〉 expression and 〈 i 〉 EGFR 〈 /i 〉 mutation in the efficacy of erlotinib in non-small-cell lung cancer (NSCLC). 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 We prospectively recruited 196 patients with stage IV or recurrent NSCLC treated with erlotinib after failure of first-line chemotherapy. Immunohistochemistry was used to evaluate 〈 i 〉 c-MET 〈 /i 〉 overexpression, silver in situ hybridization (SISH) to assess gene copy number, and real-time polymerase chain reaction to detect 〈 i 〉 EGFR 〈 /i 〉 mutations, respectively, in tumor tissue. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 The major histologic type was adenocarcinoma (66.8%). 〈 i 〉 c-MET 〈 /i 〉 was overexpressed in 55.8% (87/156) and dominant in females as well as non-squamous histology. Although 〈 i 〉 c-MET 〈 /i 〉 gene amplification and high polysomy were observed in 2.0% (3/152) and 11.2% (17/152), they did not correlate with any characteristics. 〈 i 〉 EGFR 〈 /i 〉 mutation was detected in 13.1% (20/153). The objective response rate of erlotinib was higher (61.1 vs. 3.7%, 〈 i 〉 p 〈 /i 〉 & #x3c; 0.001) and the median progression-free survival (PFS) was longer (10.2 vs. 1.9 months, 〈 i 〉 p 〈 /i 〉 & #x3c; 0.001) in EGFR-sensitizing mutations. However, 〈 i 〉 c-MET 〈 /i 〉 positivity did not show a significant correlation with response to erlotinib or PFS. 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 We reconfirmed 〈 i 〉 EGFR 〈 /i 〉 mutation as a strong predictive marker of NSCLC. However, 〈 i 〉 c-MET 〈 /i 〉 positivity was not associated with response or PFS, although 〈 i 〉 c-MET 〈 /i 〉 overexpression correlated with some clinical characteristics.
Type of Medium:
Online Resource
ISSN:
0030-2414
,
1423-0232
Language:
English
Publisher:
S. Karger AG
Publication Date:
2018
detail.hit.zdb_id:
1483096-6
detail.hit.zdb_id:
250101-6
Permalink